[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preterm-neonates\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preterm-neonates":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,82,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640398","phase-1-optimizing-preterm-infant-ampicillin-dosing-100640398",false,"NCT07610486","Optimizing PreTerm Infant Ampicillin Dosing","An Open-label, Pharmacokinetic and Safety Trial Optimizing PreTerm Infant Ampicillin Dosing","OPTI-Amp","Inclusion Criteria:\n\n* Documented informed consent from parent\u002Fguardian\n* Infants admitted to the Duke Neonatal Intensive Care Unit (NICU)\n* less than or equal to 34 completed weeks gestational age (GA) at birth and \\\u003C 7 days of life at time of screening\n* Prescribed ampicillin by provider per standard of care for evaluation of early onset sepsis\n\nExclusion Criteria:\n\n* Infant on extracorporeal support (e.g., ECMO)\n* Positive blood culture or other confirmed infection\n* At time of consent, infants with GA \\\u003C28 completed weeks who have received more than 24 hours of empiric ampicillin OR infants with GA 28 to 34 completed weeks who have received \\> 32 to 36 hours of ampicillin, depending on dosing regimen\n* Has major congenital abnormalities where survival to 30 days of life is not expected\n* Failure to obtain consent from parent\u002Fguardian\n* Receives a course of ampicillin that is longer (i.e., more doses) than the short-course defined regimen for their GA\n* Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study","ALL","0 Days","7 Days",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to learn if preterm infants who are prescribed antibiotics shortly after birth can safety receive a shorter course of antibiotics (24 to 36 hours instead of 48 hours). The main questions it aims to answer are:\n\n* Does short-course ampicillin provide high enough levels of ampicillin at 48 hours?\n* Is short-course ampicillin safe for preterm infants to receive?\n\nPreterm infants who are being prescribed ampicillin by their doctor and enroll in the study will stop ampicillin after a shorter than typical course, and researchers will collect blood samples to measure their ampicillin levels and follow them clinically to see how they do after receiving short-course ampicillin.\n\nParticipants will:\n\n* stop ampicillin earlier than 48 hours (between 24 to 36 hours, depending on how premature they are and the dosing of ampicillin their doctor has prescribed)\n* have a blood sample collected around 48 hours from when they started ampicillin\n* have their data collected until 30 days after they receive short-course ampicillin, or until hospital discharge, whichever is sooner",[29,30,31,32,33],"Early Onset Sepsis","Preterm Neonates","NICU","Ampicillin","Safety and Pharmacokinetics","NOT_YET_RECRUITING","2026-05-21",{"date":37,"type":38},"2026-05-28","ACTUAL",{"date":40,"type":22},"2026-07",{"date":42,"type":22},"2027-12",{"name":44,"class":45},"Duke University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100601389","the-peripheral-muscle-oxygenation-and-perfusion-score-as-a-new-non-invasive-tool-to-predict-elevations-in-c-reactive-protein-levels-in-neonates-100601389","NCT07109856","The Peripheral(-Muscle) Oxygenation and Perfusion Score as a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates","The Peripheral(-Muscle) Oxygenation and Perfusion Score (POPScore) a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates - a Prospective Phase II Observational Study","POP-Score","Inclusion Criteria:\n\n* birth weight ≥ 2000 grams\n* Signs of respiratory distress at time-point of inclusion (tachypnoea \\>60\u002Fmin, grunting, intercostal\u002Fsubcostal\u002Fjugular retractions, nasal flaring, supplemental oxygen or respiratory support)\n* Decision to conduct full life support\n* Written informed consent obtained within the first 6 hours after birth, before inclusion in the study\n* Age \\\u003C 6 hours\n\nExclusion Criteria:\n\n* No decision to conduct full life support\n* No written informed consent\n* Birth weight \\\u003C 2000 grams\n* Age \\> 6 hours\n* Severe congenital malformations,\n* Umbilical cord artery pH \\\u003C7.20","0 Hours","6 Hours",{"count":58,"type":22},93,"OBSERVATIONAL","This is a prospective, single-center Phase II observational study investigating the predictive value of the \"Peripheral(-muscle) Oxygenation and Perfusion Score\" (POP-Score), a novel non-invasive composite index, for early detection of infection\u002Finflammation in neonates. The POP-Score combines peripheral muscle oxygenation measured via near-infrared spectroscopy (NIRS) with routinely monitored clinical parameters (heart rate, oxygen saturation, systolic blood pressure, and subcutaneous fat thickness). The study aims to determine the optimal cut-off value of the POP-Score measured within the first 6 hours after birth to predict elevated C-reactive protein (CRP ≥20 mg\u002FL) within 48 hours. Additionally, multi-site NIRS measurements (cerebral, peripheral muscle, intestinal, and flank) will be evaluated to assess their association with inflammation. The study includes term and moderate-to-late preterm neonates (birth weight ≥2000g) with respiratory distress, admitted to the neonatal intensive care unit at the Medical University of Graz.",[62,63,64,30,65,66,67],"Prematurity, Infections","NIRS","Near Infrared Spectroscopy","Term Infant","Infection","Neonatal Sepsis, Early-Onset",[63,69,53,70,71],"near-infrared spectroscopy","neonates","preterm neonates","RECRUITING","2026-05-12",{"date":75,"type":38},"2026-05-14",{"date":77,"type":38},"2025-11-27",{"date":79,"type":22},"2028-05-01",{"name":81,"class":45},"Medical University of Graz",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100614082","the-effect-of-caffeine-therapy-in-cardiovascular-stability-in-preterm-neonates-at-assiut-university-children-hospital-nicu-100614082","NCT07274969","The Effect of Caffeine Therapy in Cardiovascular Stability in Preterm Neonates at Assiut University Children Hospital NICU","The Effect of Caffeine Therapy in Cardiovascular Stability in Preterm Neonates: a Prospective Study at the Neonatal Intensive Care Unit of Assiut University Children Hospital","Inclusion Criteria:\n\n* Preterm neonates with gestational age \\\u003C37 weeks\n* Receiving caffeine therapy for apnea of prematurity\n* Hemodynamically stable before caffeine initiation\n\nExclusion Criteria:\n\n* Presence of major congenital anomalies\n* Use of vasopressors at baseline\n* Severe intraventricular hemorrhage (Grade III-IV)","37 Weeks",{"count":91,"type":22},40,"Preterm neonates younger than 37 weeks gestational age receiving caffeine therapy for apnea of prematurity in a NICU setting.",[30,94],"Apnea of Prematurity",[96,97],"Preterm neonates","apnea of prematurity","2025-12-09",{"date":100,"type":38},"2025-12-10",{"date":102,"type":22},"2026-06-30",{"date":104,"type":22},"2027-12-30",{"name":106,"class":45},"Assiut University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":46},"100604793","endocan-and-copeptin-serum-levels-in-preterm-neonates-with-respiratory-distress-syndrome-100604793","NCT07154134","Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome","Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Prematurity.\n* Gestational age between 28 and 36 weeks.\n* Suffering from respiratory distress syndrome.\n\nExclusion Criteria:\n\n* Intrauterine growth restriction (IUGR).\n* Hypoxic ischemic encephalopathy.\n* Multiple congenital anomalies.\n* Chromosomal abnormalities.\n* Preterm less than 28 weeks.\n* Neonates with a maternal history of chorioamnionitis (early sepsis).\n* Infant of diabetic mother.\n* Prelabor rupture of membranes (PROM)\\> 2 hours.","28 Weeks","36 Weeks",{"count":91,"type":22},"This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.",[119,120,121,30,122],"Endocan","Copeptin","Serum","Respiratory Distress Syndrome","2025-08-27",{"date":125,"type":38},"2025-09-04",{"date":127,"type":38},"2025-07-10",{"date":129,"type":22},"2025-11-01",{"name":131,"class":45},"Tanta University"]